Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chronic myeloproliferative neoplasms

A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1


  1. Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagic complications of myeloproliferative disorders. Blood Rev. 2010;24:227–32.

    Article  Google Scholar 

  2. De Stefano V, Qi X, Betti S, Rossi E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost. 2016;115:240–9.

    Article  Google Scholar 

  3. Schulman S. Splanchnic vein thrombosis: what are the long-term risks? Lancet Haematol. 2018;5:e431–e2.

    Article  Google Scholar 

  4. De Stefano V, Vannucchi AM, Ruggeri M, Cervantes F, Alvarez-Larran A, Iurlo A, et al. Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. Blood Cancer J. 2016;6:e493.

    Article  Google Scholar 

  5. Lavu S, Szuber N, Mudireddy M, Yogarajah M, Gangat N, Pardanani A, et al. Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases. Am J Hematol. 2018;93:E61–4.

    Article  Google Scholar 

  6. Mascarenhas J, Mesa R, Prchal J, Hoffman R. Optimal therapy for polycythemia vera and essential thrombocythemia can only be determined by the completion of randomized clinical trials. Haematologica. 2014;99:945–9.

    CAS  Article  Google Scholar 

  7. De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G, et al. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J. 2018;8:112.

    Article  Google Scholar 

  8. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113:4829–33.

    CAS  Article  Google Scholar 

  9. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401–8.

    CAS  Article  Google Scholar 

  10. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122:3616–27.

    CAS  Article  Google Scholar 

  11. Li H. Exploring single-sample SNP and INDEL calling with whole-genome de novo assembly. Bioinformatics. 2012;28:1838–44.

    CAS  Article  Google Scholar 

  12. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–91.

    CAS  Article  Google Scholar 

  13. Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015;526:68–74.

    Article  Google Scholar 

  14. Finazzi G, De Stefano V, Barbui T. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018. Blood Cancer J. 2018;8:64.

    Article  Google Scholar 

  15. Pieri L, Paoli C, Arena U, Marra F, Mori F, Zucchini M, et al. Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. Am J Hematol. 2017;92:187–95.

    CAS  Article  Google Scholar 

Download references


This research was made possible by a grant from the National Cancer Institute of the National Institute of Health (MPN Research Consortium Grant, 5P01CA108671–09) and generous independent, unrestricted support from Roche Genentech.

Author information

Authors and Affiliations


Corresponding author

Correspondence to J. Mascarenhas.

Ethics declarations

Conflict of interest

J.M. reports clinical trial research support paid to the institution from Incyte, Roche, Novartis, CTI Biopharma, Janssen, Merck, Promedior, and Celgene; clinical trial steering committee and scientific advisory board member: Roche, CTI Biopharma, Incyte, and Celgene. M.R.B. reports clinical trial research support paid to the institution from Abbvie, AI, Astellas, Forma, Incyte, Kite, and Takeda. M.A. reports research grant support paid to institution from Incyte, CTI Biopharma, Samus Therapeutics, Janssen, and Gilead. R.T.S. reports consultancy and speaker bureau for Pharmaessentia. R.H. reports research support from Roche.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mascarenhas, J., Kosiorek, H., Prchal, J. et al. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia 33, 2974–2978 (2019).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

Further reading


Quick links